

## Completion of Security Purchase Plan

**Sunnyvale, California; 25 July 2023:** EBR Systems, Inc. (ASX: “EBR”, “EBR Systems”, or the “Company”), developer of the world’s only wireless cardiac pacing system for heart failure, is pleased to announce that it has completed the Security Purchase Plan (SPP) announced on Friday, 23 June 2023, raising approximately A\$2.66m. This follows the successful completion of a A\$30m institutional placement (Placement).

**John McCutcheon, EBR Systems’ President & Chief Executive Officer said:**

*“We are grateful for the ongoing support from our existing security holders, many of whom are long term investors, and took the opportunity to participate in the SPP at the same terms as institutions in the placement. With the capital raising now completed, we are focused on finalising our submission to the FDA and executing our commercialisation strategy to ultimately deliver superior treatment for patients suffering from cardiac rhythm diseases.”*

The SPP offer closed on Wednesday, 19 July 2023, and provided eligible EBR security holders in Australia and New Zealand with the opportunity to apply for up to A\$30,000 of new CHESS Depository Interests (CDIs) without incurring brokerage, commissions, or other transaction related costs. EBR confirms that all valid applications under the SPP were accepted in full.

In accordance with the terms contained in the SPP booklet made available to eligible security holders on Friday, 30 June 2023, the CDIs are being issued at A\$0.91 per CDI, which is the same as the issue price under the Placement.

In total 2,921,307 new CDIs (equivalent to 2,921,307 shares of common stock) will be issued under the SPP today, Tuesday, 25 July 2023, and will commence trading on Wednesday, 26 July 2023. The new CDIs will rank equally with all existing CDIs on issue. Holding statements are expected to be dispatched to security holders who participated in the SPP on Wednesday, 26 July 2023.

Funds raised under the SPP will be used to support EBR’s regulatory and commercialisation strategy, including finalising the PMA submission for FDA approval and executing key activities to support EBR’s initial commercial launch. With the completion of the capital raising, EBR is now fully funded for its pathway to FDA approval, initial commercial launch and sales growth through to H2 2025.

**ENDS**

***This announcement has been authorised for release by the EBR Systems General Disclosure Committee, a committee of the Board of Directors.***

**For more information, please contact:**

**Company**

Frank Hettmann  
Chief Financial Officer  
P: +1 408 720 1906  
E: [info@ebrsystemsinc.com](mailto:info@ebrsystemsinc.com)

**Investors**

Dean Dribbin  
Vesparum Capital  
P: +61 3 8582 4800  
E: [EBRSystems@vesparum.com](mailto:EBRSystems@vesparum.com)

## **About EBR Systems (ASX: EBR)**

Silicon Valley-based EBR Systems (ASX: EBR) is dedicated to superior treatment of cardiac rhythm disease by providing more physiologically effective stimulation through wireless cardiac pacing. The patented proprietary Wireless Stimulation Endocardially (WiSE) technology was developed to eliminate the need for cardiac pacing leads, historically the major source of complications, effectiveness and reliability issues in cardiac rhythm disease management. The initial product is designed to eliminate the need for coronary sinus leads to stimulate the left ventricle in heart failure patients requiring Cardiac Resynchronisation Therapy (CRT). Future products potentially address wireless endocardial stimulation for bradycardia and other non-cardiac indications.

## **EBR Systems' WiSE Technology**

EBR Systems' WiSE technology is the world's only wireless, endocardial (inside the heart) pacing system in clinical use for stimulating the heart's left ventricle. This has long been a goal of cardiac pacing companies since internal stimulation of the left ventricle is thought to be a potentially superior, more anatomically correct pacing location. WiSE technology enables cardiac pacing of the left ventricle with a novel cardiac implant that is roughly the size of a large grain of rice. The need for a pacing wire on the outside of the heart's left ventricle – and the attendant problems – are potentially eliminated. WiSE is an investigational device and is not currently available for sale in the US.

## **Forward-Looking Statements**

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions, and expectations and on information currently available to management. Forward-looking statements involve known and unknown risks, uncertainties, contingencies and other factors, many of which are beyond the Company's control, subject to change without notice and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to commercialize our products including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialize new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. EBR does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. EBR may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

## **Foreign Ownership Restriction**

EBR's CHES Depositary Interests (CDIs) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (Securities Act) for offers or sales which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. The holders of EBR's CDIs are unable to sell the CDIs into the US or to a US person unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. Hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.